New combo treatment aims to shrink rectal tumors before surgery
NCT ID NCT07394192
Summary
This study is testing a two-part treatment given before surgery for stage II-III rectal cancer. First, patients receive a short, focused course of radiation designed to spare certain lymph nodes. Then, they receive an immunotherapy drug (a PD-1 inhibitor) to help the immune system fight the cancer. The goal is to see if this approach can shrink or eliminate the tumor to improve surgical outcomes and long-term results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.